Company intelligence / Profile preview
ArtemiLife
- Ownership
- Private
- Development stage
- Phase 2
Overview
ArtemiLife’s lead product, ArtemiCafe® Decaf—a decaffeinated coffee containing a controlled dose of the plant extract from Artemisia annua—has shown to be safe and well-tolerated as a daily maintenance therapy following standard treatment for advanced ovarian cancer. The Phase 1 trial established safety at three cups per day with no significant toxicities. Preliminary results indicate promising anticancer activity supporting further evaluation. A Phase 2 trial is ongoing in prostate cancer patients to assess efficacy as a maintenance therapy after initial treatment.
- Therapeutic areas
- Oncology
- Modalities
- Plant-derived small molecules (notably artemisinin and derivatives)Herbal extracts/formulations delivered via tea and coffee beverages
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on ArtemiLife.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArtemiLife.